Approaches for Overcoming Obstacles to Successful Implementation in the Clinic Biomarkers have become some of the most desired clinical and research tools in the life sciences. They have the potential ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

One of the earliest examples of a vaccine biomarker assay still in use is the polio antibody neutralization assay, which evaluates the immunogenicity of different polio vaccines. This assay is used to ...

“Precision medicine” is a term we have heard a lot over the last two decades, promising to improve health outcomes by pairing the patient with the right treatment. In cancer, we do this primarily with ...

Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and ...

First central lab in EU to perform this blood-based assay under IVDR/LDT regulations, supporting inclusion and exclusion criteria in Alzheimer’s clinical trials Achieving IVDR validation for the ...

Oncology pharmacists bridge gaps in test ordering, result interpretation, and therapy access, ensuring timely and effective ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, ...